Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Vertex Pharmaceutic (VRTX)

Vertex Pharmaceutic (VRTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
VRTX
Vertex Pharmaceuticals (VRTX) Q2 Earnings Report Preview: What To Look For StockStory - Sat Aug 1, 10:05PM CDT

Vertex Pharmaceuticals (VRTX) Q2 Earnings Report Preview: What To Look For

VRTX : 477.10 (-0.95%)
Vertex: The Cystic Fibrosis Franchise Meets Its First Real Comps Test Barchart - Fri Jul 31, 4:10PM CDT

Barchart Research What to Expect from VRTX Earnings VRTX Generated July 31, 2026 Current Price $477.10 EPS Estimate $$4.30 Consensus Rating Moderate Buy Average Move 6.21% Vertex: The Cystic Fibrosis Franchise...

VRTX : 477.10 (-0.95%)
AbCellera Announces Collaboration with Vertex to Discover Multispecific T-Cell Engagers for Autoimmune Diseases and Other Conditions Business Wire - Wed Jul 29, 6:00AM CDT

AbCellera (Nasdaq: ABCL) today announced a collaboration with Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) to research, develop, manufacture, and commercialize multispecific T-cell engagers...

ABCL : 5.71 (+0.35%)
VRTX : 477.10 (-0.95%)
VRTX
3 Healthcare Stocks with Competitive Advantages StockStory - Wed Jul 22, 11:35PM CDT

3 Healthcare Stocks with Competitive Advantages

VRTX : 477.10 (-0.95%)
ZTS : 77.29 (+1.66%)
ALHC : 14.85 (-20.20%)
WDAY
1 Nasdaq 100 Stock to Keep an Eye On and 2 We Question StockStory - Wed Jul 15, 11:33PM CDT

1 Nasdaq 100 Stock to Keep an Eye On and 2 We Question

MDLZ : 62.31 (-1.22%)
VRTX : 477.10 (-0.95%)
WDAY : 160.34 (+1.41%)
Businessman pointing arrow graph corporate future growth by Marchmeena29 via iStock
What to Expect From Vertex Pharmaceuticals' Next Quarterly Earnings Report Barchart - Mon Jul 13, 8:57AM CDT

Vertex Pharmaceuticals will release its second-quarter earnings next month, and analysts anticipate a single-digit bottom-line growth.

XLV : 162.55 (-0.59%)
$SPX : 7,489.72 (+0.70%)
VRTX : 477.10 (-0.95%)
CALY
1 Momentum Stock to Research Further and 2 Facing Headwinds StockStory - Wed Jul 8, 11:47PM CDT

1 Momentum Stock to Research Further and 2 Facing Headwinds

HNI : 45.01 (+3.28%)
CALY : 18.46 (-0.38%)
VRTX : 477.10 (-0.95%)
Crinetics Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Crinetics Pharmaceuticals, Inc. - CRNX Business Wire - Wed Jul 8, 11:33AM CDT

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti , LLC (“KSF”) are investigating the proposed sale of Crinetics Pharmaceuticals...

CRNX : 83.52 (-0.13%)
VRTX : 477.10 (-0.95%)
MarketBeat.com
Vertex’s Crinetics Deal Balances Growth with Integration Risk MarketBeat - Wed Jul 8, 8:05AM CDT

Vertex Pharmaceuticals will acquire Crinetics Pharmaceuticals for $10 billion at $85 per share, adding the approved drug PALSONIFY and pipeline candidate Atumelant to expand beyond its cystic fibrosis...

CRSP : 47.99 (-0.93%)
CRNX : 83.52 (-0.13%)
VRTX : 477.10 (-0.95%)
Michael Pistillo, left, and Federico DeMarco work on the floor at the New York Stock Exchange in New York, Monday, July 6, 2026. (AP Photo/Seth Wenig)
AI stocks sink and drag markets lower worldwide Associated Press - Tue Jul 7, 3:51PM CDT

The roller-coaster ride for AI stocks snapped back down and dragged Wall Street lower

NVDA : 200.75 (+2.93%)
AAPL : 308.91 (-7.35%)
AVGO : 389.28 (+0.37%)
$SPX : 7,489.72 (+0.70%)
CRNX : 83.52 (-0.13%)
MU : 823.03 (-5.90%)
VRTX : 477.10 (-0.95%)
RIVN : 15.22 (-9.57%)
$IUXX : 28,274.20 (+0.60%)
WULF : 17.66 (-0.90%)
SPCX : 108.37 (-3.41%)
INTC : 90.20 (-1.02%)

Barchart Exclusives

Meta’s Cash Engine Is Still Running Hot, Strengthening the Bull Thesis Barchart - Sat Aug 1, 2:30PM CDT
Meta's Family of Apps generated $59.4 billion in advertising revenue during the second quarter, up 27% year-over-year. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.